Osteoprotegerin, Receptor Activator of Nuclear Factor Kappa B Ligand, and Growth Hormone/Insulin-Like Growth Factor-1 Axis in Children with Growth Hormone Deficiency
The growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis is involved in the regulation of the receptor activator of nuclear factor kappa B ligand (RANKL)/RANK/osteoprotegerin (OPG) system, but the exact mechanism of the associations is not fully explained. In this study we investigated the serum OPG and total sRANKL concentrations in short children who had differences in GH secretory status. We also investigated the associations between the GH/IGF-1 and OPG/RANKL systems in GH-deficient children during GH treatment. There were no significant differences in any anthropometric or biochemical parameters evaluated between the GH-deficient and GH-sufficient children. The OPG content and total alkaline phosphatase (ALP) activity increased significantly after the initiation of GH treatment, while total sRANKL remained unchanged. The variables baseline BMI SDS for height-age (β = 0.42; p < 0.05), baseline ALP activity (β = 0.36; p < 0.05), weight SDS for height-age at 6 months of GH treatment (β = 1.86; p < 0.01), and total ALP activity at 6 months of GH treatment (β = 0.48, p < 0.01) were identified as independent predictors of ΔOPG6-month-baseline. We conclude that OPG and total sRANKL concentrations are independent from GH secretory status in short children. OPG elevation during GH treatment is independently associated with total ALP activity and nutritional status in GH-deficient children.
KeywordsBone turnover Children Growth hormone Hormone replacement therapy Osteoprotegerin RANKL/RANK/OPG pathway
Conflicts of Interest
The authors declare no conflicts of interest in relation to this article.
All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments. The study protocol was approved by the Bioethics Committee of the Medical University of Warsaw (permit: KB/93/2016).
Informed written consent was obtained from all individual participants included in the study or from their parents and legal guardians.
- Buzi F, Maccarinelli G, Guaragni B, Ruggeri F, Radetti G, Meini A, Mazzolari E, Cocchi D (2004) Serum osteoprotegerin and receptor activator of nuclear factor κB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner’s syndrome, and rheumatoid arthritis. Clin Endocrinol 60:87–91CrossRefGoogle Scholar
- Erol M, Bostan Gayret O, Tekin Nacaroglu H, Yigit O, Zengi O, Salih Akkurt M, Tasdemir M (2016) Association of osteoprotegerin with obesity, insulin resistance and non–alcoholic fatty liver disease in children. Iran Red Crescent Med J 18(11):e41873. https://doi.org/10.5812/ircmj.41873 CrossRefPubMedPubMedCentralGoogle Scholar
- Greulich WW, Pyle SI (1969) Radiographic atlas of skeletal development of the hand and wrist. Stanford University Press, StanfordGoogle Scholar
- Kruk B, Kraj M, Centkowski P, Sokołowska U (2002) Osteoprotegerin and sRANKL serum levels in multiple myeloma patients. Cent Eur J Immunol 27(4):129–135Google Scholar
- Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE (2001) Catabolic effects of continuous human PTH in vivo is associated with sustained stimulation of RANKL and inhibition of OPG and gene–associated bone formation. Endocrinology 142:4047–4054CrossRefGoogle Scholar
- Mundy GR, Oyajobi B, Traianedes K, Dallas S, Chen D (2001) Cytokines and bone remodelling. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic, San DiegoGoogle Scholar
- Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw–Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2):309–319CrossRefGoogle Scholar
- Tanner JM (1962) Growth at adolescence. Blackwell, OxfordGoogle Scholar
- Ueland T, Bollerslev J (2005) Bone metabolism and growth hormone deficiency. In: Jorgensen JOL, Christiansen JS (eds) Frontiers in hormone research. Karger, BaselGoogle Scholar
- Ueland T, Bollerslev J, Flyvbjerg A, Hansen TB, Vahl N, Mosekilde L (2002) Effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs and OPG in Adults with acquired GH deficiency: a double–blind, randomized, placebo–controlled study. J Clin Endocrinol Metab 87:2760–2763CrossRefGoogle Scholar
- Ueland T, Odgren PR, Yndestad A, Godang K, Schreiner T, Marks SC Jr, Bollerslev J (2003) Growth hormone substitution increases gene expression of members of the IGF–1 family in cortical bone from women with adult onset growth hormone deficiency–relationship with bone turn–over. Bone 33:638–645CrossRefGoogle Scholar
- Witkowska–Sędek E, Stelmaszczyk–Emmel A, Majcher A, Demkow U, Pyrżak B (2018) The relationship between alkaline phosphatase and bone alkaline phosphatase activity and the growth hormone/insulin–like growth factor–1 axis and vitamin D status in children with growth hormone deficiency. Acta Biochim Pol 65(2):269–275PubMedGoogle Scholar
- Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis–inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95(7):3597–3602CrossRefGoogle Scholar